专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

31. 发明申请

WO2005007671A2 COMPOSITIONS AND METHODS FOR TREATING SARS 审中-公开
标题翻译：用于治疗SARS的组合物和方法
公开(公告)号：WO2005007671A2
公开(公告)日：2005-01-27
申请号：PCT/US2004/013187
申请日：2004-04-28
申请人： EPITOMICS, INC. , YU, Guoliang
发明人： YU, Guoliang
IPC分类号： C07K
CPC分类号： C07K16/10 , C12N2770/20011
摘要： The present invention provides compositions and methods of treating severe acute respiratory syndrome (SARS), and methods of reducing SARS viral load, reducing the time to SARS viral clearance, and reducing morbidity or mortality in the clinical outcomes, in patients suffering from a SARS. The present invention further provides methods of reducing the risk that an individual will develop SARS. The methods generally involve administering a therapeutically effective amount of an agent, e.g. a peptide or a monoclonal antibody, that interacts with the E2 core structure and prevents viral entry into a susceptible cell.
摘要翻译：本发明提供治疗严重急性呼吸综合征（SARS）的组合物和方法，以及在SARS患者中减少SARS病毒载量，减少SARS病毒清除时间，降低临床结果的发病率或死亡率的方法。本发明还提供减少个体发展为SARS的风险的方法。所述方法通常包括施用治疗有效量的试剂，例如，肽或单克隆抗体，其与E2核心结构相互作用并防止病毒进入易感细胞。

32. 发明申请

WO2003028666A2 ISOLATED POLYPEPTIDES AND COMPOSITIONS FROM THE VENOM OF P. TRANSVAALICUS AND METHODS OF USE 审中-公开
标题翻译：分离的多肽和来自P.Pervaalicus的生殖细胞的组合物和使用方法
公开(公告)号：WO2003028666A2
公开(公告)日：2003-04-10
申请号：PCT/US2002/031861
申请日：2002-10-04
申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA , HAMMOCK, Bruce, D. , INCEOGLU, Bora
发明人： HAMMOCK, Bruce, D. , INCEOGLU, Bora
IPC分类号： A61K
CPC分类号： C07K14/43522 , A61K38/00
摘要： The invention provides isolated polypeptides from the venom of the scorpion P. transvaalicus . The invention also provides novel scorpion antivenom compositions derived from such polypeptides, as well as methods for isolating the polypeptides and preparing scorpion antivenom compositions. The isolated polypeptides can be used to produce pharmaceutical compositions useful for treating diseases and conditions associated with ion channel function or kinin activity.
摘要翻译：本发明提供了来自蝎毒P的毒液的分离的多肽。 transvaalicus 的。本发明还提供了衍生自这些多肽的新型蝎抗蛇毒组合物，以及分离多肽和制备蝎抗蛇毒组合物的方法。分离的多肽可用于生产用于治疗与离子通道功能或激肽活性相关的疾病和病症的药物组合物。

33. 发明申请

WO2023038815A1 IRAK INHIBITOR FOR TREATING CYTOKINE RELEASE-RELATED CONDITIONS ASSOCIATED WITH INFECTION BY A RESPIRATORY VIRUS 审中-公开
公开(公告)号：WO2023038815A1
公开(公告)日：2023-03-16
申请号：PCT/US2022/041718
申请日：2022-08-26
申请人： RIGEL PHARMACEUTICALS, INC.
发明人： MARKOVTSOV, Vadim , MASUDA, Esteban
IPC分类号： C07D405/04 , C07D405/14 , C07D413/04 , C07D417/04 , C07D417/14
摘要： Disclosed herein is method for treating and/or preventing a cytokine release-related condition associated with infection by a respiratory virus, e.g., COVID-19 or influenza. In certain embodiments, the method may comprise administering a compound that inhibits Interleukin Receptor-Associated Kinase (IRAK) to a subject experiencing, or at risk of developing, the condition. In some embodiments, the compound may have a structure according to Formulas IV or VII, or a salt, solvate, N-oxide and/or prodrug thereof.

34. 发明申请

WO2022173703A1 IMMUNE RECEPTORS WITH SYNTHETIC CO-STIMULATORY DOMAINS 审中-公开
公开(公告)号：WO2022173703A1
公开(公告)日：2022-08-18
申请号：PCT/US2022/015513
申请日：2022-02-07
申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
发明人： LIM, Wendell A. , DANIELS, Kyle
IPC分类号： A61K35/13 , A61K35/17 , A61K38/00 , A61K38/16 , A61K38/22
摘要： An engineered immune receptor (e.g., a chimeric antigen receptor (CAR) or chimeric costimulatory receptor (CCR)) that contains one or more short linear motifs that bind to other intracellular signaling proteins are provided, as well as nucleic acids encoding the same, cells that contain the same and methods of use. Examples of such motifs include a PLCγ1-binding motifs and TRAF binding motifs, but other motifs may be used. These motifs are thought to recruit other proteins to the engineered immune receptor, thereby altering cellular responses.

35. 发明申请

WO2022094416A1 ENGINEERED CELLULAR ADHESION MOLECULES AND METHODS OF USE THEREOF 审中-公开
公开(公告)号：WO2022094416A1
公开(公告)日：2022-05-05
申请号：PCT/US2021/057601
申请日：2021-11-01
申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
发明人： LIM, Wendell A. , STEVENS, Adam J.
IPC分类号： A61K35/12 , A61K35/17 , A61P35/00 , C12N5/10
摘要： Described herein is an engineered cell adhesion molecule. The engineered cell adhesion molecule is a fusion protein comprising: an extracellular binding domain comprising a first binding moiety, a transmembrane domain and an intracellular domain that is capable of signaling to and reorganize the cytoskeleton of the cell upon specific binding of the first binding moiety to a second binding moiety. Various compositions, cells and methods that employ the cells are also described.

36. 发明申请

WO2022066963A1 METHOD FOR DETERMINING A VIRALLY-INFECTED SUBJECT'S RISK OF DEVELOPING SEVERE SYMPTOMS 审中-公开
公开(公告)号：WO2022066963A1
公开(公告)日：2022-03-31
申请号：PCT/US2021/051830
申请日：2021-09-23
申请人： THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
发明人： KHATRI, Purvesh , RAO, Aditya Manohar , DONATO, Michele , BEBEK, Denis Dermadi , ZHENG, Hong , JONES, Lara , TOH, Jia Ying
IPC分类号： A61P31/12 , C12Q1/6883
摘要： This disclosure provides a gene expression-based method for determining a virally-infected subject's risk of developing severe symptoms. In some embodiments, the method may comprise measuring the amount of RNA transcripts encoded by at least two genes in a sample of RNA obtained from the subject, to obtain gene expression data; and based on the gene expression data, providing a report indicating the subject's risk of developing severe symptoms. Kits and methods of treatment are also provided.

37. 发明申请

WO2022031387A1 ANTI-TIGIT ANTIBODY AND METHODS OF USE THEREOF 审中-公开
公开(公告)号：WO2022031387A1
公开(公告)日：2022-02-10
申请号：PCT/US2021/039664
申请日：2021-06-29
申请人： CRYSTAL BIOSCIENCE INC.
发明人： COLLARINI, Ellen , IZQUIERDO, Shelley , IFFLAND, Christel , HARRIMAN, William Don
IPC分类号： C07K16/30
摘要： The present disclosure provides antibodies that specifically bind to TIGIT. The antibodies find use in a variety of treatment, diagnostic, and monitoring applications, which are also described. For example, the antibody may be used to treat a patient for cancer, particularly a patient is also being treated or has been treated with an immune checkpoint inhibitor, e.g., a PD-1/PD-L1 inhibitor.

38. 发明申请

WO2021252157A1 ANTI-BDNF ANTIBODIES AND METHODS OF USE THEREOF 审中-公开
公开(公告)号：WO2021252157A1
公开(公告)日：2021-12-16
申请号：PCT/US2021/033226
申请日：2021-05-19
申请人： CRYSTAL BIOSCIENCE INC.
发明人： CHING, Kathryn , BERG, Kimberley
IPC分类号： A61P25/28 , A61P25/02 , A61P37/02 , C07K16/22 , C07K2317/21
摘要： The present disclosure provides antibodies that specifically bind to and in some cases inhibit human brain-derived neurotrophic factor (BDNF). Pharmaceutical compositions including the same are also provided, as well as a method for inhibiting BDNF signaling. The antibodies find use in a variety of treatment, diagnostic, and monitoring applications, which are also described.

39. 发明申请

WO2021141852A1 METHOD FOR PERFORMING MULTIPLE ANALYSES ON SAME NUCLEIC ACID SAMPLE 审中-公开
公开(公告)号：WO2021141852A1
公开(公告)日：2021-07-15
申请号：PCT/US2021/012079
申请日：2021-01-04
申请人： THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
发明人： JI, Hanlee P. , LAU, Billy Tsz Cheong
IPC分类号： C12Q1/6834 , C12Q1/6869 , C40B50/06 , C40B70/00
摘要： Provided herein is a method for sample analysis. In some embodiments, the method may involve: (a) incubating a nucleic acid sample with a terminal transferase and a cyclooctene-functionalized nucleotide to produced cyclooctene-functionalized nucleic acid molecules; (b) tethering the cyclooctene-functionalized nucleic acid molecules to a tetrazine-functionalized support via an Alder cycloaddition reaction; (c) performing at least two separate primer extension reactions using the tethered nucleic acid molecules as a template to produce multiple distinct sets of primer extension products; (d) separately analyzing the sets of primer extension products using different methods to produce multiple data sets; and (e) integrating the data sets.

40. 发明申请

WO2021055333A1 SYNTHETIC IMMUNE CELLS AND METHODS OF USE THEREOF 审中-公开
公开(公告)号：WO2021055333A1
公开(公告)日：2021-03-25
申请号：PCT/US2020/050838
申请日：2020-09-15
申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
发明人： LIM, Wendell A. , FRANKEL, Nicholas W.
IPC分类号： C07K14/705 , C07K16/28 , C12N5/00
摘要： The present disclosure provides a genetically modified, in vitro immune cell. The immune cell is genetically modified with one or more nucleic acids comprising nucleotide sequences encoding: a) a chimeric polypeptide comprising: i) an antibody specific for a target antigen; and ii) a binding triggered transcriptional activator; and b) a cytokine or proliferation-inducing polypeptide that increases proliferation and/or activity of an effector immune cell, where the nucleotide sequence encoding the cytokine or proliferation-inducing polypeptide is operably linked to a transcriptional control element responsive to the transcriptional activator. The present disclosure provides compositions comprising the genetically modified, in vitro immune cell; and treatment methods comprising administration of the genetically modified, in vitro immune cell.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式